Arrhythmias & electrophysiology
Incidences, risk factors, and clinical correlates of severe QT prolongation after the use of quetiapine or haloperidol
Authors' conclusion
More than 10% of patients receiving quetiapine or haloperidol therapy developed SQTP, and many of them were exposed to risk factors for SQTP. SQTP in quetiapine users was significantly associated with increased risks of ventricular arrhythmias and sudden cardiac death.
Study context
- Population
- Patients receiving quetiapine or haloperidol with baseline and follow-up ECGs, multicentre hospital system in Taiwan
- Participants
- 8,832 vs 2,341
- Exposure
- Quetiapine vs haloperidol users
- Quetiapinen = 8,832
- Haloperidoln = 2,341
- Outcome
- Severe QT prolongation (SQTP): posttreatment QTc >500 ms or QTc increase >60 ms vs baseline
Methodological detailsmulticentre, electronic medical records
- Multicentre
- Electronic medical records
Main finding
As reported in the abstract
SQTP
Observational data: associations, not effects.
Further findings
Mean increase, ms
| Outcome | Quetiapine | Haloperidol |
|---|---|---|
| Change in QTc interval | +8.3 (SD 51.8) | +8.9 (SD 44.0) |
Risk factors for severe QT prolongation (SQTP)
- Common risk factors: old age, HF, hypokalemia, amiodarone use, baseline QTc interval
- Multivariate logistic regression
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Ventricular arrhythmias and SCD associated with SQTP in quetiapine usersSQTPvs No SQTPVentricular arrhythmias, quetiapine users | 2.84 (1.95–4.13) | |
| Ventricular arrhythmias and SCD associated with SQTP in quetiapine usersSQTPvs No SQTPSCD, quetiapine users | 2.29 (1.44–3.66) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Incidences, risk factors, and clinical correlates of severe QT prolongation after the use of quetiapine or haloperidol. Heart Rhythm. Published 15 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →